LES RADIOTRACEURS AUTRES QUE LE PSMA-LIGAND POUR L’IMAGERIE TEP DU CANCER DE PROSTATE

[fr] La TEP/TDM ciblant l’antigène membranaire spécifique de la prostate (PSMA) est la technique d’imagerie de choix du cancer de prostate, elle a cependant des limites. L’objectif de cette revue est de présenter les radiotraceurs autres que ceux ciblant le PSMA pour l’imagerie TEP du cancer de prostate.

Disciplines :

General & internal medicine

Author, co-author :

Withofs, Nadia ; Centre Hospitalier Universitaire de Liège - CHU > > Service médical de médecine nucléaire et imagerie onco

Language :

French

Title :

LES RADIOTRACEURS AUTRES QUE LE PSMA-LIGAND POUR L’IMAGERIE TEP DU CANCER DE PROSTATE

Publication date :

21 September 2023

Journal title :

Médecine Nucléaire: Imagerie Fonctionnelle et Métabolique

ISSN :

0928-1258

eISSN :

1878-6820

Publisher :

Elsevier Masson, Paris, France

Special issue title :

PSMA dans le cancer de la prostate - Partie 1 : imagerie

Volume :

Issue :

Pages :

281-290

Available on ORBi :

since 08 January 2024

Statistics

Number of views

16 (2 by ULiège)

Number of downloads

10 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Parker, C., Castro, E., Fizazi, K., Heidenreich, A., Ost, P., Procopio, G., et al. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 31 (2020), 1119–1134.
Mottet N, Cornford P, van den Bergh RCN, Briers E, Eberli D, De Meerleer G, et al. EAU – EANM – ESTRO – ESUR – ISUP – SIOG Guidelines on Prostate Cancer 2023 [Available from: https://uroweb.org/guidelines/prostate-cancer].
Sheikhbahaei, S., Afshar-Oromieh, A., Eiber, M., Solnes, L.B., Javadi, M.S., Ross, A.E., et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Imaging 44 (2017), 2117–2136.
Fendler, W.P., Eiber, M., Beheshti, M., Bomanji, J., Calais, J., Ceci, F., et al. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging 50 (2023), 1466–1486.
Chow, K.M., So, W.Z., Lee, H.J., Lee, A., Yap, D.W.T., Takwoingi, Y., et al. Head-to-head comparison of the diagnostic accuracy of prostate-specific membrane antigen positron emission tomography and conventional imaging modalities for initial staging of intermediate- to high-risk prostate cancer: a systematic review and meta-analysis. Eur Urol 84 (2023), 36–48.
Hope, T.A., Eiber, M., Armstrong, W.R., Juarez, R., Murthy, V., Lawhn-Heath, C., et al. Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial. JAMA Oncol 7 (2021), 1635–1642.
Hartrampf, P.E., Huttmann, T., Seitz, A.K., Kubler, H., Serfling, S.E., Schlotelburg, W., et al. SUV(mean) on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T. Eur J Nucl Med Mol Imaging, 2023, 10.1007/s00259-023-06281-6 [Online ahead of print].
Halabi, S., Kelly, W.K., Ma, H., Zhou, H., Solomon, N.C., Fizazi, K., et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J Clin Oncol 34 (2016), 1652–1659.
Gafita, A., Calais, J., Grogan, T.R., Hadaschik, B., Wang, H., Weber, M., et al. Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol 22 (2021), 1115–1125.
Denis, C.S., Cousin, F., De Laere, B., Hustinx, R., Sautois, B.R., Withofs, N., Using, 68Ga-PSMA-11 PET/CT for therapy response assessment in patients with metastatic castration-resistant prostate cancer: an application of EAU/EANM recommendations in clinical practice. J Nucl Med 63 (2022), 1815–1821.
Fanti, S., Goffin, K., Hadaschik, B.A., Herrmann, K., Maurer, T., MacLennan, S., et al. Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. Eur J Nucl Med Mol Imaging 48 (2020), 469–476.
Hofman, M.S., Emmett, L., Sandhu, S., Iravani, A., Joshua, A.M., Goh, J.C., et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 397 (2021), 797–804.
Sartor, O., de Bono, J., Chi, K.N., Fizazi, K., Herrmann, K., Rahbar, K., et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385 (2021), 1091–1103.
Gafita, A., Marcus, C., Kostos, L., Schuster, D.M., Calais, J., Hofman, M.S., Predictors and real-world use of prostate-specific radioligand therapy: PSMA and beyond. Am Soc Clin Oncol Educ Book 42 (2022), 1–17.
Liu, I.J., Zafar, M.B., Lai, Y.H., Segall, G.M., Terris, M.K., Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 57 (2001), 108–111.
Jadvar, H., Is there use for FDG-PET in prostate cancer?. Semin Nucl Med 46 (2016), 502–506.
Buteau, J.P., Martin, A.J., Emmett, L., Iravani, A., Sandhu, S., Joshua, A.M., et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol 23 (2022), 1389–1397.
Fanti, S., Minozzi, S., Castellucci, P., Balduzzi, S., Herrmann, K., Krause, B.J., et al. PET/CT with 11C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data. Eur J Nucl Med Mol Imaging 43 (2016), 55–69.
Mapelli, P., Incerti, E., Ceci, F., Castellucci, P., Fanti, S., Picchio, M., 11C- or 18F-Choline PET/CT for imaging evaluation of biochemical recurrence of prostate cancer. J Nucl Med 57 (2016), 43S–48S.
Castellucci, P., Fuccio, C., Nanni, C., Santi, I., Rizzello, A., Lodi, F., et al. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med 50 (2009), 1394–1400.
Rodado-Marina, S., Coronado-Poggio, M., Garcia-Vicente, A.M., Garcia-Garzon, J.R., Alonso-Farto, J.C., de la Jara, A.C., et al. Clinical utility of 18F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study. BJU Int 115 (2015), 874–883.
Umbehr, M.H., Muntener, M., Hany, T., Sulser, T., Bachmann, L.M., The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol 64 (2013), 106–117.
Graziani, T., Ceci, F., Castellucci, P., Polverari, G., Lima, G.M., Lodi, F., et al. 11C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series. Eur J Nucl Med Mol Imaging 43 (2016), 1971–1979.
Detti, B., Carnevale, M.G., Lucidi, S., Burchini, L., Caini, S., Orsatti, C., et al. Choline PET/CT in recurrent prostate cancer. Front Oncol, 13, 2023, 1079808.
Schwenck, J., Rempp, H., Reischl, G., Kruck, S., Stenzl, A., Nikolaou, K., et al. Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. Eur J Nucl Med Mol Imaging 44 (2017), 92–101.
Afshar-Oromieh, A., Zechmann, C.M., Malcher, A., Eder, M., Eisenhut, M., Linhart, H.G., et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 41 (2014), 11–20.
Morigi, J.J., Stricker, P.D., van Leeuwen, P.J., Tang, R., Ho, B., Nguyen, Q., et al. Prospective comparison of 18F-Fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med 56 (2015), 1185–1190.
Oprea-Lager, D.E., Gontier, E., Garcia-Canamaque, L., Gauthe, M., Olivier, P., Mitjavila, M., et al. [18F]DCFPyL PET/CT versus [18F]fluoromethylcholine PET/CT in biochemical recurrence of prostate cancer (PYTHON): a prospective, open label, cross-over, comparative study. Eur J Nucl Med Mol Imaging, 2023, 10.1007/s00259-023-06301-5 [Online ahead of print].
Bluemel, C., Krebs, M., Polat, B., Linke, F., Eiber, M., Samnick, S., et al. 68Ga-PSMA-PET/CT in patients with biochemical prostate cancer recurrence and negative 18F-Choline-PET/CT. Clin Nucl Med 41 (2016), 515–521.
Jimbo, M., Andrews, J.R., Ahmed, M.E., Dundar, A., Karnes, R.J., Bryce, A.H., et al. Prognostic role of 11C-choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy. Prostate 82 (2022), 41–48.
Evangelista, L., Guttilla, A., Zattoni, F., Muzzio, P.C., Zattoni, F., Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol 63 (2013), 1040–1048.
Van den Bergh, L., Lerut, E., Haustermans, K., Deroose, C.M., Oyen, R., Isebaert, S., et al. Final analysis of a prospective trial on functional imaging for nodal staging in patients with prostate cancer at high risk for lymph node involvement. Urol Oncol, 33, 2015, 109 [e23–31].
Schiavina, R., Bianchi, L., Mineo Bianchi, F., Borghesi, M., Pultrone, C.V., Dababneh, H., et al. Preoperative staging with 11C-Choline PET/CT is adequately accurate in patients with very high-risk prostate cancer. Clin Genitourin Cancer 16 (2018), 305–312.e1.
Spick, C., Herrmann, K., Czernin, J., Evaluation of prostate cancer with 11C-Acetate PET/CT. J Nucl Med 57 (2016), 30S–37S.
De Visschere, P.J.L., Standaert, C., Futterer, J.J., Villeirs, G.M., Panebianco, V., Walz, J., et al. A systematic review on the role of imaging in early recurrent prostate cancer. Eur Urol Oncol 2 (2019), 47–76.
Bach-Gansmo, T., Nanni, C., Nieh, P.T., Zanoni, L., Bogsrud, T.V., Sletten, H., et al. Multisite experience of the safety, detection rate and diagnostic performance of fluciclovine (18F) positron emission tomography/computerized tomography imaging in the staging of biochemically recurrent prostate cancer. J Urol 197 (2017), 676–683.
Calais, J., Ceci, F., Eiber, M., Hope, T.A., Hofman, M.S., Rischpler, C., et al. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol 20 (2019), 1286–1294.
Tan, N., Oyoyo, U., Bavadian, N., Ferguson, N., Mukkamala, A., Calais, J., et al. PSMA-targeted radiotracers versus 18F fluciclovine for the detection of prostate cancer biochemical recurrence after definitive therapy: a systematic review and meta-analysis. Radiology 296 (2020), 44–55.
Pernthaler, B., Kulnik, R., Gstettner, C., Salamon, S., Aigner, R.M., Kvaternik, H., A prospective head-to-head comparison of 18F-Fluciclovine with 68Ga-PSMA-11 in biochemical recurrence of prostate cancer in PET/CT. Clin Nucl Med 44 (2019), e566–e573.
Ferrari, C., Mammucci, P., Lavelli, V., Pisani, A.R., Nappi, A.G., Rubini, D., et al. [18F]fluciclovine vs. [18F]fluorocholine positron emission tomography/computed tomography: a head-to-head comparison for early detection of biochemical recurrence in prostate cancer patients. Tomography 8 (2022), 2709–2722.
Abiodun-Ojo, O.A., Jani, A.B., Akintayo, A.A., Akin-Akintayo, O.O., Odewole, O.A., Tade, F.I., et al. Salvage radiotherapy management decisions in postprostatectomy patients with recurrent prostate cancer based on 18F-Fluciclovine PET/CT guidance. J Nucl Med 62 (2021), 1089–1096.
Andriole, G.L., Kostakoglu, L., Chau, A., Duan, F., Mahmood, U., Mankoff, D.A., et al. The impact of positron emission tomography with 18F-fluciclovine on the treatment of biochemical recurrence of prostate cancer: results from the LOCATE trial. J Urol 201 (2019), 322–331.
Scarsbrook, A.F., Bottomley, D., Teoh, E.J., Bradley, K.M., Payne, H., Afaq, A., et al. Effect of 18F-fluciclovine positron emission tomography on the management of patients with recurrence of prostate cancer: results from the FALCON trial. Int J Radiat Oncol Biol Phys 107 (2020), 316–324.
Lawal, I.O., Marcus, C., Schuster, D.M., Goyal, S., Adediran, O.A., Dhere, V.R., et al. Impact of 18 F-fluciclovine PET/CT findings on failure-free survival in biochemical recurrence of prostate cancer following salvage radiation therapy. Clin Nucl Med 48 (2023), e153–e159.
Zanoni, L., Bianchi, L., Nanni, C., Pultrone, C., Giunchi, F., Bossert, I., et al. [18F]-Fluciclovine PET/CT for preoperative nodal staging in high-risk primary prostate cancer: final results of a prospective trial. Eur J Nucl Med Mol Imaging 49 (2021), 390–409.
Scher, H.I., Morris, M.J., Stadler, W.M., Higano, C., Basch, E., Fizazi, K., et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol 34 (2016), 1402–1418.
Blake, G.M., Park-Holohan, S.J., Cook, G.J., Fogelman, I., Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. Semin Nucl Med 31 (2001), 28–49.
Zhou, J., Gou, Z., Wu, R., Yuan, Y., Yu, G., Zhao, Y., Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis. Skeletal Radiol 48 (2019), 1915–1924.
Benard, F., Harsini, S., Wilson, D., Zukotynski, K., Abikhzer, G., Turcotte, E., et al. Intra-individual comparison of 18F-sodium fluoride PET-CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial. Lancet Oncol 23 (2022), 1499–1507.
Fourquet, A., Rosenberg, A., Mena, E., Shih, J.J., Turkbey, B., Blain, M., et al. A comparison of 18F-DCFPyL, 18F-NaF, and 18F-FDG PET/CT in a prospective cohort of men with metastatic prostate cancer. J Nucl Med 63 (2022), 735–741.
Agrawal, A., Natarajan, A., Mithun, S., Bakshi, G., Joshi, A., Murthy, V., et al. Bone metastases in prostate cancer - Gallium-68-labeled prostate-specific membrane antigen or Fluorine 18 sodium fluoride PET/computed tomography - the better tracer?. Nucl Med Commun 43 (2022), 1225–1232.
Beheshti, M., Rezaee, A., Geinitz, H., Loidl, W., Pirich, C., Langsteger, W., Evaluation of Prostate Cancer Bone Metastases with 18F-NaF and 18F-Fluorocholine PET/CT. J Nucl Med 5 (2016), 55S–60S.
Gauthe, M., Zarca, K., Aveline, C., Lecouvet, F., Balogova, S., Cussenot, O., et al. Comparison of 18F-sodium fluoride PET/CT, 18F-fluorocholine PET/CT and diffusion-weighted MRI for the detection of bone metastases in recurrent prostate cancer: a cost-effectiveness analysis in France. BMC Med Imaging, 20, 2020, 25.
Velez, E.M., Desai, B., Jadvar, H., Treatment response assessment of skeletal metastases in prostate cancer with 18F-NaF PET/CT. Nucl Med Mol Imaging 53 (2019), 247–252.
Cook, G. Jr., Parker, C., Chua, S., Johnson, B., Aksnes, A.K., Lewington, V.J., 18F-fluoride PET:changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin). EJNMMI Res, 1, 2011, 4.
Hardcastle, N., Hofman, M.S., Lee, C.Y., Callahan, J., Selbie, L., Foroudi, F., et al. NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy. Radiat Oncol, 14, 2019, 164.
Weisman, A.J., Harmon, S.A., Perk, T.G., Eickhoff, J., Choyke, P.L., Kurdziel, K.A., et al. Quantification of bone flare on 18F-NaF PET/CT in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 22 (2019), 324–330.
Harmon, S.A., Perk, T., Lin, C., Eickhoff, J., Choyke, P.L., Dahut, W.L., et al. Quantitative assessment of early [18F]sodium fluoride positron emission tomography/computed tomography response to treatment in men with metastatic prostate cancer to bone. J Clin Oncol 35 (2017), 2829–2837.
Apolo, A.B., Lindenberg, L., Shih, J.H., Mena, E., Kim, J.W., Park, J.C., et al. Prospective study evaluating Na18F PET/CT in predicting clinical outcomes and survival in advanced prostate cancer. J Nucl Med 57 (2016), 886–892.
Lindgren Belal, S., Larsson, M., Holm, J., Buch-Olsen, K.M., Sorensen, J., Bjartell, A., et al. Automated quantification of PET/CT skeletal tumor burden in prostate cancer using artificial intelligence: the PET index. Eur J Nucl Med Mol Imaging 50 (2023), 1510–1520.
Beer, M., Montani, M., Gerhardt, J., Wild, P.J., Hany, T.F., Hermanns, T., et al. Profiling gastrin-releasing peptide receptor in prostate tissues: clinical implications and molecular correlates. Prostate 72 (2012), 318–325.
Schollhammer, R., De Clermont Gallerande, H., Yacoub, M., Quintyn Ranty, M.L., Barthe, N., Vimont, D., et al. Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples. EJNMMI Res, 9, 2019, 52.
Kurth, J., Krause, B.J., Schwarzenbock, S.M., Bergner, C., Hakenberg, O.W., Heuschkel, M., First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [177Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 47 (2020), 123–135.
Ruigrok, E.A.M., Verhoeven, M., Konijnenberg, M.W., de Blois, E., de Ridder, C.M.A., Stuurman, D.C., et al. Safety of [177Lu]Lu-NeoB treatment: a preclinical study characterizing absorbed dose and acute, early, and late organ toxicity. Eur J Nucl Med Mol Imaging 49 (2022), 4440–4451.
Schollhammer, R., Robert, G., Asselineau, J., Yacoub, M., Vimont, D., Balamoutoff, N., et al. Comparison of 68Ga-PSMA-617 PET/CT and 68Ga-RM2 PET/CT in patients with localized prostate cancer who are candidates for radical prostatectomy: a prospective, single-arm, single-center, phase II study. J Nucl Med 64 (2023), 379–385.
Gao, X., Tang, Y., Chen, M., Li, J., Yin, H., Gan, Y., et al. A prospective comparative study of [68Ga]Ga-RM26 and [68Ga]Ga-PSMA-617 PET/CT imaging in suspicious prostate cancer. Eur J Nucl Med Mol Imaging 50 (2023), 2177–2187.
Beheshti, M., Taimen, P., Kemppainen, J., Jambor, I., Muller, A., Loidl, W., et al. Value of 68Ga-labeled bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [18F]fluoromethylcholine PET-CT and multiparametric MRI-a phase I/II study. Eur Radiol 33 (2023), 472–482.
Duan, H., Baratto, L., Fan, R.E., Soerensen, S.J.C., Liang, T., Chung, B.I., et al. Correlation of 68Ga-RM2 PET with postsurgery histopathology findings in patients with newly diagnosed intermediate- or high-risk prostate cancer. J Nucl Med 63 (2022), 1829–1835.
Baratto, L., Song, H., Duan, H., Hatami, N., Bagshaw, H.P., Buyyounouski, M., et al. PSMA- and GRPR-Targeted PET: results from 50 patients with biochemically recurrent prostate cancer. J Nucl Med 62 (2021), 1545–1549.
Pederzoli, F., Raffo, M., Pakula, H., Ravera, F., Nuzzo, P.V., Loda, M., Stromal cells in prostate cancer pathobiology: friends or foes?. Br J Cancer 128 (2023), 930–939.
Mori, Y., Dendl, K., Cardinale, J., Kratochwil, C., Giesel, F.L., Haberkorn, U., et al. Fibroblast activation protein inhibitor use in oncologic and nononcologic disease. Radiology, 306, 2023, e220749.
Kratochwil, C., Flechsig, P., Lindner, T., Abderrahim, L., Altmann, A., Mier, W., et al. 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med 60 (2019), 801–805.
Chakravarty, R., Song, W., Chakraborty, S., Cai, W., Fibroblast activation protein (FAP)-targeted radionuclide therapy: which ligand is the best?. Eur J Nucl Med Mol Imaging, 2023, 10.1007/s00259-023-06338-6 [Online ahead of print].
Prive, B.M., Boussihmad, M.A., Timmermans, B., van Gemert, W.A., Peters, S.M.B., Derks, Y.H.W., et al. Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies. Eur J Nucl Med Mol Imaging 50 (2023), 1906–1918.
Backhaus, P., Gierse, F., Burg, M.C., Buther, F., Asmus, I., Dorten, P., et al. Translational imaging of the fibroblast activation protein (FAP) using the new ligand [68Ga]Ga-OncoFAP-DOTAGA. Eur J Nucl Med Mol Imaging 49 (2022), 1822–1832.
Pang, Y., Zhao, L., Meng, T., Xu, W., Lin, Q., Wu, H., et al. PET imaging of fibroblast activation protein in various types of cancer using 68Ga-FAP-2286: comparison with 18F-FDG and 68Ga-FAPI-46 in a single-center, prospective study. J Nucl Med 64 (2023), 386–394.
Loktev, A., Lindner, T., Burger, E.M., Altmann, A., Giesel, F., Kratochwil, C., et al. Development of fibroblast activation protein-targeted radiotracers with improved tumor retention. J Nucl Med 60 (2019), 1421–1429.
Galbiati, A., Zana, A., Bocci, M., Millul, J., Elsayed, A., Mock, J., et al. A dimeric FAP-targeting small-molecule radioconjugate with high and prolonged tumor uptake. J Nucl Med 63 (2022), 1852–1858.
Kessel, K., Seifert, R., Weckesser, M., Boegemann, M., Huss, S., Kratochwil, C., et al. Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imaging. Ann Nucl Med 36 (2022), 293–301.
Kesch, C., Yirga, L., Dendl, K., Handke, A., Darr, C., Krafft, U., et al. High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics. Eur J Nucl Med Mol Imaging 49 (2021), 385–389.
Bentestuen, M., Al-Obaydi, N., Zacho, H.D., FAPI-avid nonmalignant PET/CT findings: an expedited systematic review. Semin Nucl Med, 2023, 10.1053/j.semnuclmed.2023.02.001 [Online ahead of print].
Dendl, K., Koerber, S.A., Kratochwil, C., Cardinale, J., Finck, R., Dabir, M., et al. FAP and FAPI-PET/CT in malignant and non-malignant diseases: a perfect symbiosis?. Cancers (Basel), 13, 2021, 4946.
Dehdashti, F., Reimers, M.A., Shoghi, K.I., Chen, D.L., Luo, J., Rogers, B., et al. Pilot study: PARP1 imaging in advanced prostate cancer. Mol Imaging Biol 24 (2022), 853–861.
Zhang, H., Abou, D., Lu, P., Hasson, A.M., Villmer, A., Benabdallah, N., et al. [18F]-Labeled PARP-1 PET imaging of PSMA targeted alpha particle radiotherapy response. Sci Rep, 12, 2022, 13034.
Taunk, N., Carlin, S., Lee, D., Sadiq, S., Bhageri, S., Schwartz, L., 18F-FluorThanatrace (18F-FTT) positron emission tomography (PET/CT) in prostate cancer measures in vivo PARP-1 expression and is associated with adverse clinicopathologic features. J Clin Oncol, 40, 2022, 5030 [Meeting Abstract].
Zhou, D., Xu, J., Mpoy, C., Chu, W., Kim, S.H., Li, H., et al. Preliminary evaluation of a novel 18F-labeled PARP-1 ligand for PET imaging of PARP-1 expression in prostate cancer. Nucl Med Biol 66 (2018), 26–31.
De Laere, B., Oeyen, S., Mayrhofer, M., Whitington, T., van Dam, P.J., Van Oyen, P., et al. TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer. Clin Cancer Res 25 (2019), 1766–1773.
Kairemo, K., Hodolic, M., Androgen receptor imaging in the management of hormone-dependent cancers with emphasis on prostate cancer. Int J Mol Sci, 24, 2023, 8235.
Larson, S.M., Morris, M., Gunther, I., Beattie, B., Humm, J.L., Akhurst, T.A., et al. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 45 (2004), 366–373.
Kramer, G.M., Yaqub, M., Vargas, H.A., Schuit, R.C., Windhorst, A.D., van den Eertwegh, A.J.M., et al. Assessment of simplified methods for quantification of 18F-FDHT uptake in patients with metastatic castration-resistant prostate cancer. J Nucl Med 60 (2019), 1221–1227.
Fox, J.J., Gavane, S.C., Blanc-Autran, E., Nehmeh, S., Gonen, M., Beattie, B., et al. Positron emission tomography/computed tomography-based assessments of androgen receptor expression and glycolytic activity as a prognostic biomarker for metastatic castration-resistant prostate cancer. JAMA Oncol 4 (2018), 217–224.
Al Jalali, V., Wasinger, G., Rasul, S., Grubmuller, B., Wulkersdorfer, B., Balber, T., et al. Consecutive prostate-specific membrane antigen (PSMA) and antigen receptor (AR) PET imaging shows positive correlation with AR and PSMA protein expression in primary hormone-naive prostate cancer. J Nucl Med 64 (2023), 863–868.
Antunes, I.F., Dost, R.J., Hoving, H.D., van Waarde, A., Dierckx, R., Samplonius, D.F., et al. Synthesis and evaluation of 18F-enzalutamide, a new radioligand for PET imaging of androgen receptors: a comparison with 16beta-18F-Fluoro-5alpha-dihydrotestosterone. J Nucl Med 62 (2021), 1140–1145.
Storey, C.M., Altai, M., Bicak, M., Veach, D.R., Luckerath, K., Adrian, G., et al. Quantitative in vivo imaging of the androgen receptor axis reveals degree of prostate cancer radiotherapy response. Mol Cancer Res 21 (2023), 307–315.
Schollhammer, R., Quintyn Ranty, M.L., de Clermont Gallerande, H., Cavelier, F., Valverde, I.E., Vimont, D., et al. Theranostics of primary prostate cancer: beyond PSMA and GRP-R. Cancers (Basel), 15, 2023, 2345.
Park, S.Y., Na, S.J., Kumar, M., Mosci, C., Wardak, M., Koglin, N., et al. Clinical evaluation of (4S)-4-(3-[18F]Fluoropropyl)-L-glutamate (18F-FSPG) for PET/CT imaging in patients with newly diagnosed and recurrent prostate cancer. Clin Cancer Res 26 (2020), 5380–5387.
Scarpelli, M., Zahm, C., Perlman, S., McNeel, D.G., Jeraj, R., Liu, G., FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab. J Immunother Cancer, 7, 2019, 23.
Jadvar, H., Mohamed, P., Hwang, D., Chen, K., Abreu, A., Prospective comparison of mpMRI and 18F-FMAU PET:CT in image-guided prostate biopsy for detection of cancer: preliminary results. J Nucl Med, 63, 2022, 2534.
Dai, D., Yu, J., Huang, T., Li, Y., Wang, Z., Yang, S., et al. PET imaging of new target CDK19 in prostate cancer. Eur J Nucl Med Mol Imaging, 2023.
Parida, G.K., Tripathy, S., Datta Gupta, S., Singhal, A., Kumar, R., Bal, C., et al. Adenocarcinoma prostate with neuroendocrine differentiation: potential utility of 18F-FDG PET/CT and 68Ga-DOTANOC PET/CT Over 68Ga-PSMA PET/CT. Clin Nucl Med 43 (2018), 248–249.
Shu, Q., Li, X., Chen, X., Chen, Y., Cai, L., 177Lu-DOTATATE therapy in a case of castrate-resistant prostate cancer with neuroendocrine differentiation. Clin Nucl Med 48 (2023), e371–e373.
Korsen, J.A., Kalidindi, T.M., Khitrov, S., Samuels, Z.V., Chakraborty, G., Gutierrez, J.A., et al. Molecular imaging of neuroendocrine prostate cancer by targeting delta-like ligand 3. J Nucl Med 63 (2022), 1401–1407.
Wu, W., Yu, F., Zhang, P., Bu, T., Fu, J., Ai, S., et al. 68Ga-DOTA-NT-20.3 neurotensin receptor 1 PET imaging as a surrogate for neuroendocrine differentiation of prostate cancer. J Nucl Med 63 (2022), 1394–1400.
1Haffner, M.C., Zwart, W., Roudier, M.P., True, L.D., Nelson, W.G., Epstein, J.I., et al. Genomic and phenotypic heterogeneity in prostate cancer. Nat Rev Urol 18 (2021), 79–92.
Park, P.S.U., Raynor, W.Y., Sun, Y., Werner, T.J., Rajapakse, C.S., Alavi, A., 18F-Sodium Fluoride PET as a diagnostic modality for metabolic, autoimmune, and osteogenic bone disorders: cellular mechanisms and clinical applications. Int J Mol Sci, 22, 2021, 650.